Måløv, Denmark
Novo Nordisk began construction in October of 2014 on a $127 million biomedical research facility in Måløv, Denmark, to support the development of treatments for diabetes. Housing 350 employees, the three-story, 177,600-sf project will be built as two laboratory wings connected by a central structure housing offices and an auditorium. Occupancy is expected in early 2016.
Source
